Glaxo 'downplayed' warning on heart-attack risk from Aids drug

The multinational drugs company GlaxoSmithKline (GSK) downplayed an early warning about the rising number of people who have suffered potentially fatal heart attacks following the use of its £600m anti-Aids drug, which is taken daily by tens of thousands of people around the world.

GSK was officially told of the possible risk in May 2005, three years before it issued a statement to its investors saying that the findings of an even stronger potential link between heart attacks and its antiviral drug abacavir are both “unexpected” and “unconfirmed”.

The company also said that it could find no association between abacavir use and heart attacks following a trawl through its internal data, however it failed to mention that its own summary of product characteristics issued when the drug was launched in the late 1990s had actually described “mild myocardial degeneration” in the hearts of mice and rats given the drug for two years.

Some scientists involved with monitoring the safety of Aids drugs are privately furious with GSK for downplaying the significance of one of the biggest safety trials into abacavir – one of several anti-viral drugs taken by Aids patients as part of combined HIV therapy – when the findings were published last month.

“GSK was extraordinarily well prepared in terms of a statement that downplayed the significance of the findings,” said one of the scientists close to the safety study.

“As a consequence, people are now confused and perplexed because they think there is something wrong with the study itself because GSK said that it cannot find any evidence to support the findings of a link with myocardial infarction [heart attacks],” he said.

Alastair Benbow, European medical director for GSK, said that the company takes any new information about the safety of its drugs seriously but it did not want to highlight what may be “spurious observations” relating to abacavir.

The first public sign that abacavir may be linked with increased risk of heart attacks emerged this April when The Lancet published the worldwide “DAD” study into the adverse reactions to anti-HIV drugs, involving clinical observations of 33,347 Aids patients across Europe, Australia and the United States.

The study found that the risk of having a heart attack in patients taking abacavir was almost double that of HIV patients who did not take the drug as part of their combination therapy. The study also found that the risk of heart attacks returned to normal six months after they had stopped taking abacavir.

Independent scientists who analysed the DAD findings said in The Lancet that the data were not strong enough to establish a causal connection because that would have required a different type of study; but they emphasised that the observed increase in the risk of heart attacks was “too strong to ignore”.

The same scientists also pointed out that the studies on which GSK relied for casting doubt on the DAD study were themselves not powerful enough to discount a link between the drug and the risk of heart attacks.

To coincide with the Lancet publication, GSK issued a statement to its investors playing down the association between abacavir and heart attacks, saying that the findings of the DAD study were unexpected and that no possible biological mechanism to explain it has been found.

The statement did not mention that GSK had been made aware three years earlier of a report involving 34 cases of heart attacks in patients taking abacavir. The report or “signal” was sent to the company in May 2005 by an international drug-monitoring centre operated by the WHO in Uppsala, Sweden.

“We sent them the signal and we gave them the chance to comment on it. We received a reply, which was in effect a no-reply. They said ‘thank-you’ and that was all,” said Dr Ralph Edwards, director of the Uppsala Monitoring Centre.

“The purpose of our signal was to do exactly that, to make them aware that there is at least a risk. We expect countries and companies to take it seriously. I am disappointed with GSK’s response in the published literature,” Dr Edwards said.

Dr Benbow said that GSK investigated the Uppsala signal in 2005 and carried out a check of its own internal data, as well as the database of the American Food and Drug Administration, but could not replicate the finding. “So there was not a signal in our internal database or that of the FDA,” he said.

Didier Lapierre, GSK’s vice president of clinical development, said in the statement to investors at the time of the April DAD study that the increased relative risk of heart attacks remained low in absolute terms and that patients should not discontinue treatment without medical advice.

“The DAD findings are unexpected, since we have not seen similar findings in our studies, and we are unaware of any potential biological mechanism that would explain them. In our own analysis of trials involving more than 9,600 patients, no increased risk of heart attack associated with abacavir was found,” Dr Lapierre said.

Scientists involved in the DAD study, however, believe that a possible biological mechanism is that abacavir is converted into a potentially toxic substance called carbovir once it gets into the cells of the heart.

They cite GSK’s own research on animals in support of this hypothesis which found that abacavir is associated with mild myocardial degeneration in the heart tissue of rats and mice given the drug for a period of two years. Dr Benbow said that the company has investigated this hypothesis but has not found any data to support it.

However, Professor Jens Lundgren of Copenhagen University, who led the DAD study, said that his team is actively pursuing this proposal as a possible explanation for the doubling of the risk of heart attacks seen in abacavir patients.

“We do have a sense of what could be the problem. However, we were completely crushed in the GSK media machine when our study came out. GSK were made aware of the findings at the end of last year when we had the first meetings with them,” Professor Lundgren said.

The US Federal Drug Administration and the European Medicines Agency have both said that at present there is no reason to change the prescribing information for abacavir, however they are both reviewing the safety data on abacavir in relation to heart attacks and are expected to issue their conclusions and recommendations later this year.

Suggested Topics
News
people And here is why...
Arts and Entertainment
Amazon has added a cautionary warning to Tom and Jerry cartoons on its streaming service
tv
Voices
voicesBy the man who has
Sport
Arsene Wenger tried to sign Eden Hazard
footballAfter 18 years with Arsenal, here are 18 things he has still never done as the Gunners' manager
PROMOTED VIDEO
Life and Style
The new Windows 10 Start Menu
tech
News
business
Arts and Entertainment
Kristen Stewart and Robert Pattinson star in The Twilight Saga but will not be starring in the new Facebook mini-movies
tvKristen Stewart and Stephenie Meyer will choose female directrs
News
William Hague
people... when he called Hague the county's greatest
News
More than 90 years of car history are coming to an end with the abolition of the paper car-tax disc
newsThis and other facts you never knew about the paper circle - completely obsolete today
News
peopleStella McCartney apologises over controversial Instagram picture
News
ebooksAn unforgettable anthology of contemporary reportage
Arts and Entertainment
Twerking girls: Miley Cyrus's video for 'Wrecking Ball'
arts + ents
Arts and Entertainment
Ed Sheeran performs at his Amazon Front Row event on Tuesday 30 September
musicHe spotted PM at private gig
News
people'I’d rather have Fred and Rose West quote my characters on childcare'
Arts and Entertainment
There has been a boom in ticket sales for female comics, according to an industry survey
comedyFirst national survey reveals Britain’s comedic tastes
News
Kim Jong Un gives field guidance during his inspection of the Korean People's Army (KPA) Naval Unit 167
newsSouth Korean reports suggest rumours of a coup were unfounded
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

General Cover Teacher

£120 - £125 per day: Randstad Education Luton: Are you looking for part time/ ...

SEN (SLD/PMLD) Teacher

£120 - £130 per day: Randstad Education Chelmsford: Are you a quailed Teacher ...

General Cover Teacher

£120 - £125 per day: Randstad Education Luton: Currently looking for teachers ...

SEN Teaching Assistant Runcorn

£50 per day: Randstad Education Cheshire: SEN Teaching Assistant EBD , Septemb...

Day In a Page

Ebola outbreak: The children orphaned by the virus – then rejected by surviving relatives over fear of infection

The children orphaned by Ebola...

... then rejected by surviving relatives over fear of infection
Pride: Are censors pandering to homophobia?

Are censors pandering to homophobia?

US film censors have ruled 'Pride' unfit for under-16s, though it contains no sex or violence
The magic of roundabouts

Lords of the rings

Just who are the Roundabout Appreciation Society?
Why do we like making lists?

Notes to self: Why do we like making lists?

Well it was good enough for Ancient Egyptians and Picasso...
Hong Kong protests: A good time to open a new restaurant?

A good time to open a new restaurant in Hong Kong?

As pro-democracy demonstrators hold firm, chef Rowley Leigh, who's in the city to open a new restaurant, says you couldn't hope to meet a nicer bunch
Paris Fashion Week: Karl Lagerfeld leads a feminist riot on 'Boulevard Chanel'

Paris Fashion Week

Lagerfeld leads a feminist riot on 'Boulevard Chanel'
Bruce Chatwin's Wales: One of the finest one-day walks in Britain

Simon Calder discovers Bruce Chatwin's Wales

One of the finest one-day walks you could hope for - in Britain
10 best children's nightwear

10 best children's nightwear

Make sure the kids stay cosy on cooler autumn nights in this selection of pjs, onesies and nighties
Manchester City vs Roma: Five things we learnt from City’s draw at the Etihad

Manchester City vs Roma

Five things we learnt from City’s Champions League draw at the Etihad
Martin Hardy: Mike Ashley must act now and end the Alan Pardew reign

Trouble on the Tyne

Ashley must act now and end Pardew's reign at Newcastle, says Martin Hardy
Isis is an hour from Baghdad, the Iraq army has little chance against it, and air strikes won't help

Isis an hour away from Baghdad -

and with no sign of Iraq army being able to make a successful counter-attack
Turner Prize 2014 is frustratingly timid

Turner Prize 2014 is frustratingly timid

The exhibition nods to rich and potentially brilliant ideas, but steps back
Last chance to see: Half the world’s animals have disappeared over the last 40 years

Last chance to see...

The Earth’s animal wildlife population has halved in 40 years
So here's why teenagers are always grumpy - and it's not what you think

Truth behind teens' grumpiness

Early school hours mess with their biological clocks
Why can no one stop hackers putting celebrities' private photos online?

Hacked photos: the third wave

Why can no one stop hackers putting celebrities' private photos online?